ClinicalTrials.gg

Program

bimagrumab

Also written as “Bimagrumab”, “BYM338” and “LY3985863”.

Its studies are mostly in Myositis, Inclusion Body · Obesity · Sarcopenia · Cachexia · Heart Failure, Diastolic, led by 2 companies.

Furthest: phase 3, since Aug 15, 201318 company-led studies, 2 open or runningNext primary completion: Jul 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis120 open or runningphase 3since Aug 15, 2013Aug 12, 2011none ahead
Eli Lilly62 open or runningphase 2since Oct 16, 2022Oct 16, 2022Jul 2029phase 2 · NCT07920887
  • Named in Eli Lilly’s own pipeline as Bimagrumab, phase 2, as of Oct 29, 2026 (source).

Also a collaborator on its studies: versanis-bio-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Aug 12, 2011.

  1. Apr 12, 2013Phase 2 study in CachexiaNovartis · NCT01868685
  2. Aug 15, 2013Phase 3 study in Myositis, Inclusion BodyNovartis · NCT01925209 · 251 enrolled · United States, Australia, Belgium and more
  3. Mar 20, 2014Phase 3 study in Myositis, Inclusion BodyNovartis · NCT02250443 · 10 enrolled · United States
  4. May 8, 2014Phase 2 study in Muscular AtrophyNovartis · NCT02152761 · 251 enrolled · United States, Argentina, Australia and more
  5. Dec 10, 2014Phase 2 study in SarcopeniaNovartis · NCT02333331 · 217 enrolled · United States, Australia, Belgium and more
  6. Apr 30, 2015Phase 2 study in SarcopeniaNovartis · NCT02468674 · 160 enrolled · United States, Australia, Belgium and more
  7. Jul 9, 2015Phase 3 study in Myositis, Inclusion BodyNovartis · NCT02573467 · 211 enrolled · United States, Australia, Belgium and more
  8. Dec 24, 2016Phase 2 study in Diabetes Mellitus, Type 2Novartis · NCT03005288 · 78 enrolled · United States, United Kingdom
  9. Oct 16, 2022Eli Lilly's first study: phase 2 study in ObesityNew to Eli LillyEli Lilly · NCT05616013 · 507 enrolled · United States, Australia, New Zealand
  10. Oct 14, 2024Phase 2 study in ObesityEli Lilly · NCT06643728 · 252 enrolled · United States
  11. Mar 18, 2025Phase 1 study in HealthyEli Lilly · NCT06890611 · 125 enrolled · United States
  12. Mar 24, 2025Phase 2 study in ObesityEli Lilly · NCT06901349 · United States, Argentina, Canada and more
  13. Jun 12, 2025Phase 1 study in HealthyEli Lilly · NCT07030127 · 24 enrolled · China
  14. Oct 29, 2026Phase 2 study in Heart Failure, DiastolicEli Lilly · NCT07920887 · 540 planned · United States, Hungary, Italy and more

Ahead

  1. Jul 2029Primary completion: phase 2 study in Heart Failure, DiastolicEli Lilly · NCT07920887

TargetBeta

“A human monoclonal antibody directed against type II activin receptors (ActRII; ActR2), with potential muscle-sparing and anti-cachectic activities. Upon administration, bimagrumab binds to ActRII, which prevents the binding of the natural ligands, myostatin and activin, to activin receptors and …”NCIt, read by Claude
“Activin receptor type-2B antagonist”ChEMBL 37, by rule

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07920887Heart Failure, Diastolic · United States, Hungary, Italy and more2Not yet recruitingEli LillyJul 2029540
NCT07030127Healthy · China1CompletedEli LillyFeb 24, 202624
NCT06901349Obesity · United States, Argentina, Canada and more2WithdrawnEli LillyJun 10, 20250
NCT06890611Healthy · United States1CompletedEli LillySep 26, 2025125
NCT06643728Obesity · United States2Active, not recruitingEli LillyJan 16, 2026252
NCT05616013Obesity · United States, Australia, New Zealand2CompletedEli LillyMay 16, 2024507
NCT03005288Diabetes Mellitus, Type 2 · United States, United Kingdom2CompletedNovartisMar 21, 201978
NCT02573467Myositis, Inclusion Body · United States, Australia, Belgium and more3CompletedNovartisAug 17, 2016211
NCT02468674Sarcopenia · United States, Australia, Belgium and more2CompletedNovartisDec 3, 2018160
NCT02333331Sarcopenia · United States, Australia, Belgium and more2CompletedNovartisJun 26, 2018217
NCT02152761Muscular Atrophy · United States, Argentina, Australia and more2CompletedNovartisMay 14, 2018251
NCT02250443Myositis, Inclusion Body · United States3CompletedNovartisAug 23, 201610
NCT01925209Myositis, Inclusion Body · United States, Australia, Belgium and more3CompletedNovartisJan 6, 2016251
NCT01868685Cachexia2WithdrawnNovartisJan 20150
NCT01669174Pulmonary Disease, Chronic Obstructive · United States, Netherlands, United Kingdom2CompletedNovartisDec 201467
NCT01601600Skeletal Muscle · United States2CompletedNovartisDec 201340
NCT01433263Cachexia · United States, Lithuania, Romania and more2CompletedNovartisApr 201457
NCT01423110Myositis, Inclusion Body · United States2CompletedNovartisMay 201214

How it is read

Names in the registry

  • “Bimagrumab”, 6 entries
  • “BYM338”, 4 entries
  • “bimagrumab”, 3 entries
  • “LY3985863”, 1 entry
  • “BYM338 10 mg/kg”, 1 entry

Codes read as this program: LY3985863.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.